88 related articles for article (PubMed ID: 7538898)
1. B7-1 expression by a non-antigen presenting cell-derived tumor.
Antonia SJ; Muñoz-Antonia T; Soldevila G; Miller J; Flavell RA
Cancer Res; 1995 Jun; 55(11):2253-6. PubMed ID: 7538898
[TBL] [Abstract][Full Text] [Related]
2. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
Fenton RG; Turcovski-Corrales SM; Taub DD
J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
[TBL] [Abstract][Full Text] [Related]
3. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
4. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production.
Schweitzer AN; Sharpe AH
J Immunol; 1998 Sep; 161(6):2762-71. PubMed ID: 9743334
[TBL] [Abstract][Full Text] [Related]
5. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
[TBL] [Abstract][Full Text] [Related]
6. Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86.
Schweitzer AN; Borriello F; Wong RC; Abbas AK; Sharpe AH
J Immunol; 1997 Mar; 158(6):2713-22. PubMed ID: 9058805
[TBL] [Abstract][Full Text] [Related]
7. B7 costimulatory molecules from malignant cells in patients with b-cell chronic lymphoproliferative disorders trigger t-cell proliferation.
Trentin L; Perin A; Siviero M; Piazza F; Facco M; Gurrieri C; Galvan S; Adami F; Agostini C; Pizzolo G; Zambello R; Semenzato G
Cancer; 2000 Sep; 89(6):1259-68. PubMed ID: 11002221
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
9. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation.
Chaux P; Moutet M; Faivre J; Martin F; Martin M
Lab Invest; 1996 May; 74(5):975-83. PubMed ID: 8642792
[TBL] [Abstract][Full Text] [Related]
11. Activated T hybridomas induce upregulation of B7-1 on bystander B lymphoma cells by a contact-dependent interaction utilizing CD40 ligand.
Jones KW; Hackett CJ
Cell Immunol; 1996 Nov; 174(1):42-53. PubMed ID: 8929453
[TBL] [Abstract][Full Text] [Related]
12. The immunogenic potential of human fetal retinal pigment epithelium and its relation to transplantation.
Rezai KA; Semnani RT; Patel SC; Ernest JT; van Seventer GA
Invest Ophthalmol Vis Sci; 1997 Nov; 38(12):2662-71. PubMed ID: 9375586
[TBL] [Abstract][Full Text] [Related]
13. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
[TBL] [Abstract][Full Text] [Related]
14. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
15. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen.
Bai XF; Gao JX; Liu J; Wen J; Zheng P; Liu Y
Cancer Res; 2001 Sep; 61(18):6860-7. PubMed ID: 11559562
[TBL] [Abstract][Full Text] [Related]
16. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
17. Mutual regulation between B7-1 (CD80) expressed on T cells and IL-4.
Schweitzer AN; Sharpe AH
J Immunol; 1999 Nov; 163(9):4819-25. PubMed ID: 10528182
[TBL] [Abstract][Full Text] [Related]
18. Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.
Lamphear JG; Stevens KR; Rich RR
J Immunol; 1998 Jan; 160(2):615-23. PubMed ID: 9551895
[TBL] [Abstract][Full Text] [Related]
19. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
20. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.
Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B
J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
